You might also like
Roivant Sciences Ltd. (ROIV) is a biopharmaceutical company dedicated to improving patient health by accelerating the development and commercialization of innovative medicines and technologies. The company operates through a unique model of creating subsidiaries, known as "Vants," which focus on specific medicines and technologies. Roivant's offerings include FDA-approved treatments for dermatological conditions and collaborations in drug development, alongside investments in health technology startups.
- Product Revenue - Generates income primarily from the sale of VTAMA\u00ae (tapinarof), a topical treatment for plaque psoriasis in adults, with additional potential applications for atopic dermatitis pending regulatory approval.
- License, Milestone, and Other Revenue - Includes income from licensing agreements and milestone payments, such as collaborations with partners like Japan Tobacco Inc..
- Technology Vants - Develops and deploys health technology solutions aimed at improving the efficiency of drug development and commercialization processes.
- Incubation of Startups - Supports discovery-stage companies and health technology startups that align with its mission to enhance healthcare innovation.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Eric Venker Executive | President and Chief Operating Officer | Board Member at Immunovant, Inc. and several private biopharmaceutical companies | Eric Venker joined Roivant in 2014 and has held various roles, including COO. He has a background in medicine and pharmacy, with degrees from Yale and St. Louis College of Pharmacy. | |
Matthew Gline Executive | Chief Executive Officer | Board Member at Datavant | Matthew Gline has been the CEO of Roivant since January 2021. He joined Roivant in March 2016 and previously served as CFO. He has a background in finance and risk analytics, having worked at Goldman Sachs and co-founded Fourthree. | View Report → |
Mayukh Sukhatme Executive | President and Chief Investment Officer | Board Member at Immunovant, Inc. and several private biopharmaceutical companies | Mayukh Sukhatme joined Roivant in 2015. He has been instrumental in capital allocation and development strategies, leading to multiple FDA approvals and positive Phase 3 studies. He holds an M.D. from Harvard Medical School. | |
Rakhi Kumar Executive | Chief Accounting Officer | Board Member at NeuroPace, Inc. and Roivant Social Ventures | Rakhi Kumar has been CAO since August 2018, leading accounting and financial operations. She has prior experience at The Medicines Company and Ernst & Young. | |
Richard Pulik Executive | Chief Financial Officer | None | Richard Pulik became CFO in October 2021. He previously held senior roles at Novartis and has a background in finance and business development. | |
Daniel Gold Board | Director | CEO of QVT Financial LP, Board Member at Okeanis Eco Tankers Corp., Awilco Drilling PLC, NAXS AB | Daniel Gold has been a Director since 2020. He is the founder and CEO of QVT Financial LP and has a background in investment across various industries. | |
Ilan Oren Board | Chair of the Board of Directors | Co-CEO of Dexcel Pharma, Board Member at Clexio Biosciences and Kriya Therapeutics | Ilan Oren has been a Director since 2014 and Chair since 2023. He has extensive experience in the pharmaceutical industry and holds an A.B. in Economics from Harvard. | |
James C. Momtazee Board | Director | Managing Partner of Patient Square Capital, Board Member at BridgeBio Pharma, Apollo Therapeutics, Kriya Therapeutics, Medical Device Manufacturers Association | James C. Momtazee has been a Director since September 2021. He has over 28 years of investment experience, primarily in healthcare. | |
Meghan FitzGerald Board | Director | Board Member at Tenet Healthcare, Founder of K2HealthVentures, Adjunct Professor at Columbia University | Meghan FitzGerald joined the Board in March 2023. She has extensive experience in healthcare strategy and investment. | |
Melissa Epperly Board | Director | Board Member at Kinnate Biopharma Inc. and Nautilus Biotechnology | Melissa Epperly joined as a Director in June 2022. She has a background in finance, having served as CFO at Zentalis Pharmaceuticals and other companies. |
-
Can you elaborate on your commitment to advance 1402 into myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), regardless of the upcoming data from the high-dose batoclimab studies? Will you proceed with pivotal studies in both indications even if the data doesn't meet expectations?
-
Given the recent investment you made in Immunovant before the release of critical data, can you explain the rationale behind this timing? If you believe the valuation is attractive, why not acquire the entire asset now and capitalize on the potential pricing dislocation?
-
With the initiation of the Phase II BEACON study in cutaneous sarcoidosis, which seems relatively small, can you discuss how the trial is powered, particularly on the CSAMI score? How do you anticipate the placebo group will perform, and does this indication leverage existing infrastructure from Kinevant?
-
As you await the top-line dermatomyositis (DM) Phase III readout in the second half of 2025, how do you assess the competitive landscape, especially if Argenx successfully completes its own Phase III in DM? What are your expectations for brepocitinib in this context?
-
Regarding the upcoming LNP litigation summary judgment, can you help us understand the possible range of outcomes? Is there a scenario where Moderna or the U.S. government would be liable for all patent infringement liabilities, or could there be partial liability based on contract terms?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
ZORYVE (roflumilast) | A topical PDE4 inhibitor, identified as a potential competitor to VTAMA. |
OPZELURA (ruxolitinib) | A topical Janus kinase inhibitor, identified as a potential competitor to VTAMA. |
VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | Neonatal Fc receptor blockers, identified as potential competitors to IMVT-1402 and batoclimab. |
Nipocalimab and RYSTIGGO (rozanolixizumab-noli) | Anti-FcRn antibodies, identified as potential competitors to IMVT-1402 and batoclimab. |
TEPEZZA (teprotumumab-trbw) | An insulin-like growth factor-1 receptor inhibitor, identified as a potential competitor to batoclimab. |
Dazukibart | An interferon beta (IFN-beta) inhibitor, identified as a potential competitor to brepocitinib. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Silicon Therapeutics LLC | 2021 | Completed in March 2021, the deal was valued at approximately $450.0 million with a structured payment of $350.0 million in common stock at closing and a $100.0 million tranche made later in cash and shares, with the fair value of the consideration being $402.4 million mainly attributed to IPR&D. |
CF Principal Investments, LLC | 2022 | Planned as of February 2022, the agreement established a committed equity facility of up to $250.0 million with an initial issuance of 145,986 common shares priced at 99% of VWAP, which was later terminated on September 21, 2022 in favor of a new sales agreement. |
Recent press releases and 8-K filings for ROIV.
- Leadership Changes: Immunovant’s CEO Pete Salzmann is retiring; Eric Venker is the new CEO and Tiago Girao has been appointed CFO to drive the company's next phase
- Pipeline Focus & Expansion: The company is narrowing development to 6 indications—including registrational programs in Graves' disease, MG, and CIDP, plus POC studies in CLE—and expanding IMVT-1402 to target Sjögren’s Disease and Cutaneous Lupus Erythematosus to support growth
- Financial Guidance: Immunovant expects its cash runway to extend through major trial data readouts through 2027, with multiple catalyst events from 2026 onward
- Investor Call: A live investor call is scheduled for April 21, 2025, at 8 a.m. EDT to discuss these updates
- Phase 3 MG Study: Batoclimab met its primary endpoint in AChR+ myasthenia gravis patients with a 5.6-point improvement in MG-ADL at Week 12 for the 680mg arm and a 4.7-point improvement for the 340mg arm, demonstrating robust efficacy compared to placebo.
- Phase 2b CIDP Study: Initial data showed a 1.8-point improvement in aINCAT scores at Week 12 and an 84% responder rate among patients achieving >70% IgG reduction, indicating meaningful benefit in CIDP.
- The announcement underscores the company’s strategic focus on advancing next-generation FcRn inhibitors, with plans to leverage these results to guide further development of assets like IMVT-1402, while batoclimab is not being pursued for regulatory approval in these indications.
- Vision and Alignment: The management emphasized a clear vision to build a premier biopharma company by leveraging their diverse pipeline through selective in-licensing and acquisitions, with executive incentives strongly aligned with shareholder performance over a 5‐year target period and subsequent 3-year stock holding requirements.
- Pipeline Developments: Upcoming critical data readouts for Immunovant’s batoclimab in myasthenia gravis (MG) and CIDP are expected to validate their approach to deep IgG suppression, while the next-generation asset 1402 is poised to offer improved potency and a favorable safety profile with a roadmap toward multiple registrational studies.
- Brepocitinib and Expanded Indications: The company is advancing brepocitinib into registrational studies for orphan conditions like dermatomyositis and NIU, targeting significant unmet needs in these markets, thus broadening their therapeutic footprint.
- LNP Litigation and Additional Assets: Roivant is actively pursuing litigation over lipid nanoparticle patents against major COVID-19 vaccine producers, with key trial dates ahead, and is also progressing other pipeline assets such as the inhaled sGC activator mosliciguat for PH-ILD, highlighting a busy catalyst period.